Every Hair Loss Treatment, Ranked by Evidence: A Physician's Honest Guide

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc. — Drug-Free Hair Regrowth Series

You have twelve browser tabs open. One says finasteride is the only thing that works. One says finasteride ruined a man's life. One is selling a $90 bottle of gummies with a photograph of someone else's hair on it. And you've been at this long enough that you've stopped believing any of them.

What you want is the thing nobody seems willing to give you: a straight ranking. What actually works, in order, according to the evidence — including the options I don't sell.

So that's what this is. I'm going to rank every major hair loss intervention by the strength of the clinical evidence behind it, and I'm going to put pharmaceuticals at the top, because that is where the evidence puts them. If I rigged this table toward the drug-free category I formulate in, the article would be worthless to you and you'd know it by the third row.

Then, at the end, I'll explain the thing that the ranking doesn't tell you — which is why the highest-ranked treatment is frequently the wrong treatment for a specific person.

How I'm Ranking: What "Evidence" Means Here

Tiers reflect the strength and quality of the clinical evidence, not effect size alone, not safety, and not suitability for you. Roughly:

• Tier 1 — Multiple large randomized, placebo-controlled trials, replicated, with regulatory review. High confidence the effect is real.
• Tier 2 — Randomized controlled evidence exists but is limited by sample size, duration, blinding, heterogeneous protocols, or industry sponsorship. Probably real, magnitude uncertain.
• Tier 3 — Small studies, mechanistic plausibility, or evidence confined to a specific subgroup. Possible benefit, weak proof.
• Tier 4 — Little or no credible evidence for the population it's marketed to, or evidence that applies only to deficient individuals and is misapplied to everyone else.

Note that Tier 4 does not mean "scam." Several Tier 4 entries have genuine evidence in a different population than the one being sold to. That distinction is the single most useful thing in this article.

The Comparison Table

Tier 1: The Strongest Evidence

Finasteride

Oral finasteride at 1 mg inhibits type II 5α-reductase and substantially lowers serum DHT. The pivotal randomized trials demonstrated significant hair count improvement versus placebo in men with androgenetic alopecia, with benefit sustained over extended follow-up (Kaufman et al., 1998). Its most reliable property is arresting progression.

Real drawbacks, stated plainly. Sexual adverse events — reduced libido, erectile dysfunction, ejaculatory disorder — occurred in low single-digit percentages in the trials, modestly above placebo. Beyond the trials, case series have reported sexual dysfunction persisting after discontinuation (Irwig & Kolukula, 2011; Irwig, 2012), a picture discussed in the literature as post-finasteride syndrome (Traish, 2020). That entity remains poorly characterized — no established prevalence, mechanism, or diagnostic criteria — but regulators in several jurisdictions have updated labeling to reference persistent sexual dysfunction and mood effects. It is also teratogenic; women who are or could become pregnant must not handle broken tablets.

Verdict: the most effective single agent for male pattern hair loss, and it belongs at the top of this table. Prescribed and monitored by your own physician, with genuinely informed consent.

Dutasteride

Dual inhibition of both type I and type II 5α-reductase produces greater DHT suppression than finasteride, and comparative trial evidence supports superior hair count outcomes (Olsen et al., 2006). Used off-label for hair loss in many markets. Higher magnitude, longer half-life, same class of risks with greater suppression. A physician-supervised second-line option.

Minoxidil

Topical minoxidil shortens telogen, pushes resting follicles into anagen early, and prolongs anagen. Five percent produced significantly greater hair count improvement than 2% and placebo at 48 weeks in men (Olsen et al., 2002), and randomized data support efficacy in female pattern hair loss (Lucky et al., 2004). It does not touch DHT — it stimulates growth on top of an ongoing androgenic process, which is why it combines logically with a DHT-directed agent.

Real drawbacks: twice-daily indefinitely, a start-up shed at two to eight weeks, vehicle dermatitis frequently traced to propylene glycol in liquid formulations, facial hypertrichosis in some women, loss of drug-maintained gains within three to six months of stopping, and contraindication in pregnancy and breastfeeding.

Low-Level Laser Therapy

Red light around 650–670 nm is proposed to act on mitochondrial cytochrome c oxidase, increasing follicular ATP availability (Avci et al., 2014). A randomized, double-blind, sham-device-controlled trial reported significant hair count improvement with a laser comb in men (Leavitt et al., 2009). I place LLLT at the low end of Tier 1 deliberately: the trials are real and sham-controlled, but the field is dominated by manufacturer-sponsored studies, device parameters vary enormously between products, and a studied device and a cheap unlabeled one are not the same intervention. Buy on published specifications or not at all.

Oral Antiandrogens in Women

Spironolactone and related antiandrogens block the androgen receptor and have supporting evidence in female pattern hair loss, including a substantial prospective cohort comparison (Sinclair et al., 2005). Requires monitoring, carries a strict pregnancy contraindication, and is a physician-managed therapy.

Hair Transplantation

Not a drug — a redistribution. Occipital follicles are intrinsically androgen-resistant and retain that resistance when relocated (donor dominance). Outcomes are heavily operator-dependent, and transplantation does not stop progression of native hair, so medical maintenance alongside it is standard.

Tier 2: Real Evidence, Real Limitations

Microneedling. A randomized evaluator-blinded study found microneedling plus minoxidil outperformed minoxidil alone in men with androgenetic alopecia (Dhurat et al., 2013). Mechanistically coherent, consistently positive in small studies, and cheap. Not a monotherapy, and improvised at-home technique carries genuine infection and scarring risk.

Botanical 5α-reductase inhibitors. A randomized double-blind trial of botanically derived 5αR inhibitors reported improvement in androgenetic alopecia (Prager et al., 2002). A pumpkin seed oil RCT reported greater hair count increase than placebo over 24 weeks (Cho et al., 2014). EGCG has been studied in the lab for promotion of follicle growth ex vivo (Kwon et al., 2007). Importantly, a head-to-head comparison found finasteride superior to Serenoa repens, while the botanical arm still produced benefit (Rossi et al., 2012). That is the honest summary of this category: real, smaller.

Peptides. Signal peptides such as Acetyl Tetrapeptide-3 and Biotinoyl Tripeptide-1 have been studied in the lab for follicular signalling and extracellular matrix interactions. Independent replication is limited, and delivery matters enormously — a peptide in a rinse-off product has seconds of contact time and belongs in a leave-on step.

PRP. Autologous platelet concentrate injected into the scalp; randomized placebo-controlled work has reported hair count and density benefit (Gentile et al., 2015). The obstacle is heterogeneity — centrifugation protocols, platelet concentrations, activation methods, and session schedules differ across every published study, so "PRP" describes a category, not a standardized treatment. Expensive, repeat-session dependent.

Nutritional correction. The evidence here is strong and narrow: correcting documented deficiency helps; supplementing a replete person does not (Almohanna et al., 2019). Low ferritin is the classic miss (Trost et al., 2006). Get the labs — thyroid panel, ferritin, vitamin D, zinc — before buying anything. Unmonitored iron supplementation is not benign.

Ketoconazole 2% shampoo. Reported to improve density and pilary index in men with androgenetic alopecia over long-term use, with anti-androgenic activity proposed alongside its antifungal action (Piérard-Franchimont et al., 1998; Inui & Itami, 2007). Small, dated studies; modest effect; prescription at 2%; and constrained by rinse-off contact time.

Tier 3: Plausible, Poorly Proven

Scalp massage. A small study reported increased hair thickness after standardized daily scalp massage, proposing mechanical stretching of dermal papilla cells as the mechanism (Koyama et al., 2016). It was small and uncontrolled. But it is free, pleasant, and low-risk, so the cost-benefit is favorable even on weak evidence — provided you massage with fingertips rather than nails and don't add friction damage.

Rosemary oil. A comparative trial found diluted rosemary oil comparable to 2% minoxidil over six months in androgenetic alopecia (Panahi et al., 2015). One trial, no placebo arm, and 2% minoxidil is the weaker comparator. Reasonable as an adjunct, properly diluted. Not a substitute for a Tier 1 agent.

Topical melatonin. Small studies with limited replication (Fischer et al., 2012). Mechanistically interesting, evidentially thin.

Most supplements in replete individuals. If your labs are normal, additional micronutrients are unlikely to do anything for your hair. This applies to products I sell as much as to anyone else's: a supplement's value is in supplying cofactors that are actually short.

Tier 4: Where the Money Goes to Die

Biotin without deficiency. A review of biotin for hair loss found evidence of benefit only in genuine biotin deficiency, which is rare in people eating an ordinary diet (Patel et al., 2017). Worse, biotin is not merely inert — high-dose biotin interferes with immunoassays, and the FDA has issued a safety communication because it can distort troponin results (risking a missed heart attack) and thyroid panels. If you take high-dose biotin, tell your doctor before any blood test. This is the one Tier 4 entry with real downside.

"Hair growth gummies" in replete people. A multivitamin sold at a therapeutic price point with no clinical trial behind the finished formula. The genuine harm is opportunity cost: months spent on a product that cannot work, during which pattern loss progresses.

Laser devices of unspecified output. Photobiomodulation is device-specific. A unit that doesn't publish wavelength, power density, and treatment time isn't a cheaper version of a studied device — it's an unknown.

Undiluted essential oils. There is a randomized aromatherapy trial showing benefit — for alopecia areata, an autoimmune condition, using a diluted blend in carrier oil (Hay et al., 1998). That result is regularly misquoted as applying to pattern hair loss, which it does not. Applied neat, essential oils cause contact dermatitis, sensitisation, and occasionally chemical burns. Always dilute in a carrier; never assume an areata result transfers to androgenetic alopecia.

Why Evidence Rank and Personal Fit Are Different Questions

The highest-ranked treatment is frequently the wrong treatment for a specific person. Evidence rank answers "does this work on average, in a studied population?" Personal fit answers "should you take it?" Five things break the correspondence:

1. Contraindications are absolute. If you are pregnant, trying to conceive, or breastfeeding, minoxidil, finasteride exposure, and spironolactone are simply off the table — the evidence rank is irrelevant. Cardiac disease, certain renal conditions, and a range of drug interactions similarly remove options regardless of how well they perform in trials.

2. Side-effect tolerance is legitimately personal. A 2% risk of sexual dysfunction is a trivial number to one person and an unacceptable one to another. That is not innumeracy — it is a value judgment about which only you have standing. A patient who weighs finasteride's profile and declines is making a rational decision and deserves a real alternative plan, not a lecture.

3. Adherence beats efficacy. A Tier 1 treatment applied three times a week outperforms nothing and underperforms a Tier 2 treatment used daily for two years. When I assess a regimen, the first question is never "is this the strongest option?" — it's "will this person still be doing this in eighteen months?"

4. Cost and access are clinical variables. PRP at repeated in-clinic sessions, a properly specified laser device, and transplantation are all gated by money. A plan you cannot sustain financially is not a plan.

5. Diagnosis changes the entire table. Everything above assumes androgenetic alopecia. If you actually have telogen effluvium, traction alopecia, alopecia areata, or a scarring alopecia, this table is the wrong map — scarring alopecias in particular are urgent, because the follicular destruction is permanent and the window closes. Get a diagnosis before you optimize a treatment.

So the correct sequence is: diagnosis first, then contraindications, then your own honest tolerance and sustainability, and only then the evidence ranking as the tiebreaker among the options that survive. The table is a tool for the last step, not the first.

The Bottom Line

Ranked by evidence: finasteride, dutasteride, minoxidil, well-specified LLLT, oral antiandrogens in women, and transplantation occupy Tier 1. Microneedling, botanical 5α-reductase inhibitors, peptides, PRP, nutritional correction in documented deficiency, and ketoconazole shampoo occupy Tier 2 — real evidence, smaller or less certain effects. Scalp massage, rosemary oil, topical melatonin, and supplements in already-replete people sit in Tier 3. Biotin without deficiency, generic hair gummies, unspecified laser devices, and undiluted essential oils are Tier 4, and one of them can distort your cardiac lab results.

That's the ranking, and I've put the drugs I don't sell at the top because that's where the data puts them.

But the ranking is not your answer. Your answer is what remains after you subtract what you're contraindicated for, what you won't tolerate, what you can't afford, and what you won't actually keep doing — and then rank that shortlist. For a very large number of people, particularly women of reproductive age and men who have weighed finasteride and said no, the surviving shortlist is drug-free. Building that tier properly, with layered mechanisms and a twelve-month commitment, is a legitimate plan — not a consolation prize.

Get the diagnosis. Get the labs. Then choose the best thing you'll still be doing in two years.

Dr. Susan Lin's Clinical Perspective

"I put finasteride at the top of my own table knowing perfectly well I formulate in the tier below it, because a ranking that flatters the author's inventory is worth nothing to the person reading it. What I'd add is that in twenty years of practice the ranking has almost never been the deciding factor. The deciding factors are pregnancy status, side-effect tolerance, cost, and — above all — whether someone will still be applying something on a Tuesday night in month fourteen. I have watched patients on the single most effective agent available do worse than patients on a modest layered regimen, purely on adherence. The other error I see constantly is optimizing treatment before establishing diagnosis. If the underlying process is a scarring alopecia, every row in that table is the wrong answer and the window is closing while you shop. Diagnose first. Rank second. Then pick what you'll sustain."

— Dr. Susan Lin, MD, Physician Formulator, MD HAIR

Mechanism Spotlight: Why Combination Therapy Beats Any Single Agent

Look closely at the Tier 1 and Tier 2 entries and a pattern emerges: they act on entirely different points in the same pathway. Finasteride and dutasteride reduce DHT production by inhibiting 5α-reductase. Spironolactone blocks the androgen receptor downstream of it. Minoxidil ignores androgens altogether and manipulates the hair cycle, forcing telogen follicles into anagen and extending anagen once started. LLLT targets follicular energetics at the mitochondrion. Microneedling triggers wound-healing and growth-factor signalling. Nutritional correction supplies the substrate for keratin synthesis, and scalp care manages the inflammatory environment around the bulb. These are not competing answers to one question — they are separate levers on a multifactorial process, which is precisely why combination regimens consistently outperform monotherapy in the literature, most visibly where microneedling plus minoxidil beat minoxidil alone (Dhurat et al., 2013). This has a direct implication for the drug-free tier. No single botanical, peptide, or device matches a pharmaceutical head-to-head — Rossi and colleagues showed exactly that when finasteride outperformed Serenoa repens (Rossi et al., 2012). But a drug-free approach was never meant to be one molecule substituting for one drug. Its logic is the same additive logic that makes combination therapy work: several modest, mechanistically distinct effects — botanical support, peptide follicular signalling, inflammatory control, corrected nutrition — stacked in the tissue where miniaturization occurs.

Recommended Reading

Pillar guides on mdhair.com:

• Drug-Free Hair Loss Treatment — The Complete Guide
• Hormonal Hair Loss: Every Stage, Every Cause
• The Science of Verbascoside
• Meet Dr. Susan Lin, MD

Related articles in this series:

• Male Pattern Hair Loss: The Drug-Free Options, Honestly Assessed — the long-form version of the finasteride decision
• How Long Does It Take to Regrow Hair? A Realistic Timeline — because adherence is the variable that outranks everything in this table

Not sure where your hair loss fits? Take the MD HAIR Quiz.

Our established sister property, md-factor.com, is the official companion site and holds the wider MD® formulation archive.

MD HAIR Product Recommendation

MD HAIR™ Restoration Starter Kit

If your shortlist — after subtracting contraindications, side-effect tolerance, cost, and what you'll realistically sustain — comes out drug-free, then the question becomes doing that tier properly rather than piecemeal. That is what the MD HAIR™ Restoration Starter Kit is for. It assembles the drug-free layers into one protocol: MD® Scalp Essential as the scalp-health foundation (mandelic acid, caffeine, lilac stem-cell extract with CLA glutathione), the leave-on peptide serum MD® Follicle Energizer working through peptide signalling at the follicle, and MD Nutri Hair™ supplying nutritional cofactors keratin synthesis depends on — plus its lead compound, lilac-derived verbascoside, studied in the lab on human dermal papilla cells, where it prevented testosterone-induced cell death at a statistically significant level (cell studies, not human trials). The design principle is the one in the Mechanism Spotlight above — stack several modest, mechanistically distinct effects rather than hope one ingredient behaves like a drug.

In a 30-day in-office consumer use study of MD Nutri Hair™ in 30 subjects, 95% saw improved hair appearance, 90% reported better manageability, and 75% reported increased fullness — self-reported, no placebo control. In a 119-day Spincontrol North America study of the two-step topical serum system in 24 participants, 71% agreed their hair growth had improved — self-reported, open-label, no placebo group, with the report noting the overall satisfaction rate was not significantly validated. Individual results vary. Drug-free and hormone-free, with no taper required if you stop. Plan on ninety days minimum before evaluating and twelve months before deciding. Physician-formulated by Dr. Susan F. Lin, M.D., under the MD® mark (U.S. Reg. No. 4,471,494), and made in FDA-registered, GMP-compliant facilities in the USA.

Genuine MD HAIR™ and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart.

Learn more about drug-free options at mdhair.com/pages/drug-free-hair-loss-treatment

References (click to check)

1. Kaufman KD, et al. (1998). Finasteride in the treatment of men with androgenetic alopecia. JAAD, 39(4), 578–589
2. Irwig MS, Kolukula S. (2011). Persistent sexual side effects of finasteride for male pattern hair loss. Journal of Sexual Medicine, 8(6), 1747–1753
3. Irwig MS. (2012). Persistent sexual side effects of finasteride: could they be permanent? Journal of Sexual Medicine, 9(11), 2927–2932
4. Traish AM. (2020). Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and Sterility, 113(1), 21–50. PMID 32033719
5. Olsen EA, et al. (2006). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss. JAAD, 55(6), 1014–1023
6. Olsen EA, et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. JAAD, 47(3), 377–385
7. Lucky AW, et al. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. JAAD, 50(4), 541–553
8. Avci P, et al. (2014). Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in Surgery and Medicine, 46(2), 144–151. PMID 23970445
9. Leavitt M, et al. (2009). HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia. Clinical Drug Investigation, 29(5), 283–292
10. Sinclair R, Wewerinke M, Jolley D. (2005). Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology, 152(3), 466–473
11. Dhurat R, et al. (2013). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. International Journal of Trichology, 5(1), 6–11
12. Prager N, et al. (2002). A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. JACM, 8(2), 143–152
13. Rossi A, et al. (2012). Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia. International Journal of Immunopathology and Pharmacology, 25(4), 1167–1173
14. Cho YH, et al. (2014). Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia. Evidence-Based Complementary and Alternative Medicine, 549721
15. Kwon OS, et al. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine, 14(7–8), 551–555
16. Gentile P, et al. (2015). The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Translational Medicine, 4(11), 1317–1323
17. Almohanna HM, et al. (2019). The role of vitamins and minerals in hair loss: a review. Dermatology and Therapy, 9(1), 51–70. PMID 30547302
18. Trost LB, Bergfeld WF, Calogeras E. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. JAAD, 54(5), 824–844
19. Piérard-Franchimont C, et al. (1998). Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology, 196(4), 474–477. PMID 9669136
20. Inui S, Itami S. (2007). Reversal of androgenetic alopecia by topical ketoconazole: relevance of anti-androgenic activity. Journal of Dermatological Science, 45(1), 66–68
21. Koyama T, et al. (2016). Standardized scalp massage results in increased hair thickness by inducing stretching forces to dermal papilla cells in the subcutaneous tissue. ePlasty, 16, e8
22. Panahi Y, et al. (2015). Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed, 13(1), 15–21
23. Fischer TW, et al. (2012). Topical melatonin for treatment of androgenetic alopecia. International Journal of Trichology, 4(4), 236–245
24. Patel DP, Swink SM, Castelo-Soccio L. (2017). A review of the use of biotin for hair loss. Skin Appendage Disorders, 3(3), 166–169
25. Hay IC, Jamieson M, Ormerod AD. (1998). Randomized trial of aromatherapy: successful treatment for alopecia areata. Archives of Dermatology, 134(11), 1349–1352
26. U.S. Food and Drug Administration. Safety communication: biotin interference with laboratory tests

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR, a line of drug-free hair products by La Cañada Ventures, Inc. — physician-formulated since 2008, under the MD® mark (U.S. Reg. No. 4,471,494). MD HAIR™ and MD Nutri Hair™ products are cosmetics and dietary supplements; they are not intended to diagnose, treat, cure, or prevent any disease. This article is for educational purposes and does not constitute medical advice. Do not start, stop, or change any medication — including finasteride, dutasteride, minoxidil, or spironolactone — without consulting your own physician.

Pregnancy and breastfeeding: because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.